| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA213685
Max Phase: Preclinical
Molecular Formula: C40H35N5O4
Molecular Weight: 649.75
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=C1c2ccccc2-c2c1c1ccccc1c(=O)n2CCNCCNCCNCCn1c2c(c3ccccc3c1=O)C(=O)c1ccccc1-2
Standard InChI: InChI=1S/C40H35N5O4/c46-37-29-13-5-3-11-27(29)35-33(37)25-9-1-7-15-31(25)39(48)44(35)23-21-42-19-17-41-18-20-43-22-24-45-36-28-12-4-6-14-30(28)38(47)34(36)26-10-2-8-16-32(26)40(45)49/h1-16,41-43H,17-24H2
Standard InChI Key: QSRCECHXALOPRL-UHFFFAOYSA-N
Associated Targets(Human)
MDA-MB-435 (38290 Activities)
DU-145 (51482 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SN12C (47755 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
OVCAR-3 (48710 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
UACC-62 (47335 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SF-539 (44845 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HCT-116 (91556 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HOP-62 (47048 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Panel (12 tumour cell lines) (42 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
TOP1 Tclin DNA topoisomerase I (7553 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 649.75 | Molecular Weight (Monoisotopic): 649.2689 | AlogP: 4.21 | #Rotatable Bonds: 12 |
| Polar Surface Area: 114.23 | Molecular Species: BASE | HBA: 9 | HBD: 3 |
| #RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: | CX Basic pKa: 8.96 | CX LogP: 2.97 | CX LogD: 0.79 |
| Aromatic Rings: 6 | Heavy Atoms: 49 | QED Weighted: 0.17 | Np Likeness Score: -0.05 |
References
| 1. Nagarajan M, Morrell A, Antony S, Kohlhagen G, Agama K, Pommier Y, Ragazzon PA, Garbett NC, Chaires JB, Hollingshead M, Cushman M.. (2006) Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors., 49 (17): [PMID:16913702] [10.1021/jm060046o] |
Source
Source(1):